Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719038 | 0.86 | L3MBTL1 (0.62) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL718378 | 0.85 | MAPT (0.48) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL719984 | 0.84 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL720934 | 0.81 | CA12 (0.59) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL716746 | 0.80 | MAPT (0.69) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL28717643 | 0.79 | NR3C1 (0.49) | MEN1KMT2AMAPTTP53SMN1; SMN2 | |
| SCHEMBL718166 | 0.78 | KMT2A (0.52) | ALDH1A1MAPK1L3MBTL1MEN1KMT2A | |
| SCHEMBL23928575 | 0.77 | CA12 (0.66) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL718931 | 0.77 | CA12 (0.51) | ALDH1A1MAPK1MAPTCA12CA9 | |
| SCHEMBL31466406 | 0.76 | L3MBTL1 (0.43) | ALDH1A1MAPK1L3MBTL1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ALDH1A1 504/4885MAPK1 320/4885L3MBTL1 4088/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ALDH1A1 504/4885MAPK1 320/4885L3MBTL1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.